CBFB: A Promising Drug Target and Biomarker for the Treatment of Fibrosis

Target Name: CBFB

NCBI ID: G865

CBFB

CBFB: A Promising Drug Target and Biomarker for the Treatment of Fibrosis

Introduction

Fibrosis is a complex biological process that involves the progressive accumulation of extracellular matrix (ECM) components, leading to the deterioration of tissues and organs. Fibrosis is a major contributor to diseases such as heart failure, chronic obstructive pulmonary disease (COPD), and chronic kidney disease, and its severity can vary from mild to life-threatening. The development of effective treatments for fibrosis remains a major challenge in the field of medicine.

CBFB, or Core-binding factor subunit beta (isoform 2), is a protein that has been identified as a potential drug target and biomarker for the treatment of fibrosis. CBFB plays a critical role in the regulation of cell-cell adhesion and cytoskeletal organization , and its dysfunction has been implicated in the development and progression of many diseases, including fibrosis.

The Dysfunction of CBFB in Fibrosis

CBFB is a protein that consists of two subunits: alpha (isoform 1) and beta (isoform 2). Alpha subunit is a 21-kDa protein that contains a N-terminal domain, a central 尾-sheet, and a C-terminal domain . Beta subunit is a 19-kDa protein that contains a N-terminal domain, a central 尾-sheet, and a C-terminal domain. The N-terminal domain of both subunits contains a conserved region that is involved in protein-protein interactions and may play a role in the regulation of cell-cell adhesion.

Studies have shown that CBFB is involved in the regulation of cell-cell adhesion and cytoskeletal organization, and its dysfunction has been implicated in the development and progression of many diseases, including fibrosis. For example, studies have shown that CBFB plays a critical role in the regulation of T-cell biology, and its dysfunction has been implicated in the development of T-cell lymphomas.

CBFB as a Drug Target

CBFB has been identified as a potential drug target for the treatment of fibrosis due to its involvement in the regulation of cell-cell adhesion and cytoskeletal organization. Fibroids, which are non-cancerous polyps that can develop in various tissues, including the lungs, heart , and kidneys, are composed of ECM components that can cause symptoms such as abdominal pain, coughing, and difficulty breathing.

Recent studies have shown that CBFB can be targeted with small molecules, such as inhibitors of the N-endopeptide-loop region of CBFB, which is involved in the regulation of cell-cell adhesion. These inhibitors have been shown to reduce the size and number of fibroids in animal models of fibrosis.

CBFB as a Biomarker

CBFB has also been identified as a potential biomarker for the diagnosis and monitoring of fibrosis. Fibrosis can be detected using various biomarkers, such as fibrograms, which are measures of the thickness of ECM components in tissue samples. However, the accuracy of these biomarkers can be limited, as they may not be able to detect the early stages of fibrosis.

CBFB has been shown to be a potential biomarker for fibrosis due to its stability and reproducibility. Fibrograms can be used to detect changes in the thickness of ECM components over time, which may indicate the presence of fibrosis. Additionally, the function of CBFB has been shown to be involved in the regulation of cell-cell adhesion, which may be an indicator of the severity of fibrosis.

Conclusion

CBFB is a protein that has been identified as a potential drug target and biomarker for the treatment of fibrosis. Its dysfunction

Protein Name: Core-binding Factor Subunit Beta

Functions: Forms the heterodimeric complex core-binding factor (CBF) with RUNX family proteins (RUNX1, RUNX2, and RUNX3). RUNX members modulate the transcription of their target genes through recognizing the core consensus binding sequence 5'-TGTGGT-3', or very rarely, 5'-TGCGGT-3', within their regulatory regions via their runt domain, while CBFB is a non-DNA-binding regulatory subunit that allosterically enhances the sequence-specific DNA-binding capacity of RUNX. The heterodimers bind to the core site of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL3 and GM-CSF promoters. CBF complexes repress ZBTB7B transcription factor during cytotoxic (CD8+) T cell development. They bind to RUNX-binding sequence within the ZBTB7B locus acting as transcriptional silencer and allowing for cytotoxic T cell differentiation

The "CBFB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CBFB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets